Phase III Antibiotic Garenoxacin Will Be Out-Licensed, Schering Says

Schering-Plough will out-license U.S. rights to the Phase III quinolone antibiotic garenoxacin due to potential conflicts of interest related to the company's primary care marketing agreement with Bayer